ArticleUrolithiasis2025
In-vitro and in-vivo evaluation for anti-urolithiasis potential of Ficus racemosa L. bark extract in ethylene glycol induced rat model.
Article in Urolithiasis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Protective effects of Rhus coriaria L. fruit extract against experimental calcium oxalate nephrolithiasis via modulation of oxidative stress and renal injury.Urolithiasis · 2026Article
- Modulating effects of bee venom (Apis mellifera intermissa) against ethylene glycol-induced oxidative nephrotoxicity in male mice.International urology and nephrology · 2026Article
- Petroselinum crispum (Parsley) Leaf Extract Attenuates Ethylene Glycol-Induced Nephrolithiasis Through Antioxidant and Renoprotective Effects.BioMed research international · 2026Article
- Letter to editor: In-vitro and in-vivo evaluation for anti-urolithiasis potential of ficus racemosa L. bark extract in ethylene glycol induced rat model.Urolithiasis · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Even after stone removal, urolithiasis might reoccur, affecting patients' quality of life. Our study tested Ficus racemosa L. bark hydroalcoholic extract (FRBHE) for anti-urolithiasis efficacy. First, the extract was tested for dissolution of calcium oxalate as well as calcium phosphate crystal in-vitro. Also in-vivo, 0.75% w/v of Ethylene glycol (EG) for 28 days with drinking water was used to induce urolithiasis. By day 14, EG consumption developed calcium oxalate crystals, altered urine pH, urine volume, levels of minerals, and nephrological indicators in urine and serum that indicates urolithiasis. From day 15 to day 28, while EG consumption continued, FRBHE (200 and 400 mg/kg) and marketed formulation Cystone tablet (150 mg/kg) were given to rats. FRBHE treatment lowered the calcium, uric acid and urea and increase the creatinine, magnesium in urine in contrast to disease control group (P < 0.001). In plasma of EG consuming rats, level of calcium, potassium, magnesium, creatinine, uric acid and urea were elevated compared to normal rats (P < 0.001). FRBHE, similar to Cystone, normalized plasma parameters. On days 14 and 28, glutathione (P < 0.001) and catalase (P < 0.05) decreased and malondialdehyde (P < 0.001) increased in the kidney as compared to normal control group, indicating oxidative stress in urolithiatic rats. Treatment groups showed increased levels of glutathione and decreased malondialdehyde indicating oxidative stress recovery as compared to disease control group ((P < 0.001). Histopathological study of the kidney reveals medication therapy can reduce EG and calcium oxalate stone-mediated cellular damage. Current study proves Ficus racemosa L. bark may inhibit urolithiasis in-vitro and in-vivo warranting further clinical trials to confirm therapeutic efficacy.
Indexed as
Identifiers
40244440What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.